However, it is also being shown that the recovered immune function in these natural revertants might be very variable, suggesting that the effects of ERT might be unique to each patient. In this report, we describe the molecular and immunologic abnormalities associated with ADA deficiency in a child PD98059 mouse diagnosed at the age of 1 month with T-B- SCID, in whom low numbers of PB T lymphocytes were found later at the age of 23 months and became normal by 50 months of age. This was associated initially

with homozygosity for a mutation that later resulted in a mosaic because of a monoallelic reversion of this mutation documented in his T cells. As this child was not eligible for HSCT or GT, he was placed on ERT, and we describe the molecular and immunologic changes due to partial immune reconstitution and the clinical outcome after 17 months of ERT. Patient and control subjects.  Our patient was a boy diagnosed with ADA-SCID at the Primary Immunodeficiencies Clinic in the University of Antioquia in Medellin (Colombia), that we followed until the age 67 months. Selleck Compound Library Written informed consent approved by the IRB at the University of Antioquia was obtained from both parents and healthy age- and sex-matched controls. Immunophenotyping of peripheral blood lymphocytes.  Peripheral blood lymphocytes (PBL) from EDTA

whole blood were stained with different combinations of fluorochrome-conjugated monoclonal antibodies against CD3, CD4, CD8, CD19, CD21, CD27, IgD, CD16, CD56, TCRαβ, TCRγδ, CD45RA and CD45RO (eBioscience

Inc, San Diego, CA, USA and BD Biosciences, San Jose, CA, USA) for 30 min at room temperature, followed by treatment with lysing solution (BD FACS Lysing Solution®; BD Biosciences) for 10 min to remove RBC. After this, the cells were washed twice in PBS (Dulbecco’s phosphate-buffered saline; Sigma Aldrich, Saint Louis, MO, USA), fixed in 200 μl of 2% formaldehyde and read on a FACScan Flow Cytometer equipped with a 388-nm laser (Becton Dickinson, San Jose, CA, USA). Files were analysed using the software FlowJo v8.2 (TreeStar Inc, Ashland, OR, USA), and the results were compared with the controls as indicated [15]. Mutation analysis.  Genomic DNA from the patient Adenosine triphosphate and controls was extracted from whole blood, PBL and buccal epithelial cells as well as from negatively enriched CD3+ T cells using a DNA Purification Kit (Puregene, Gentra Systems, Minneapolis, MN, USA). Primers and PCR conditions used for the amplification of all ADA exons have been described previously [5, 16]. The nucleotide sequences were determined using the genetic analyzer ABI-PRISM 3100 (AB Applied Biosystems, Foster City, CA, USA) and analysed using the Sequencher software v. 4.8 (Gene Codes Corporation, MI, USA). ADA activity and adenine nucleotide content in RBC.